Skip to Content

Fondaparinux Sodium

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Anticoagulant agent: Direct, selective inhibitor of blood-coagulation factor Xa

Chemical Name

Metyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-OR-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranos (WHO)

Foreign Names

  • Fondaparinuxum natricum (Latin)
  • Fondaparinux natrium (German)
  • Fondaparinux sodique (French)
  • Fondaparinux sodico (Spanish)

Generic Names

  • Fondaparinux Sodium (OS: BAN, USAN, JAN)
  • Fondaparin sodium (IS)
  • Fondaparinux (IS)
  • IC 851589 (IS)
  • Org 35140 (IS: Organon)
  • Pentasaccharid Faktor Xa-Inhibitor (IS: selektiv)
  • SR 90107A (IS: SanofiSynthela)
  • Xantidar (IS)

Brand Names

  • Arixtra
    Aspen, Bosnia & Herzegowina; Aspen, Belgium; Aspen, Switzerland; Aspen, United Kingdom; Aspen, Ireland; Aspen, Iceland; Aspen, Macedonia; Aspen, Malaysia; Aspen France, France; Aspen Pharma, Cyprus; Aspen Pharma, Latvia; Clinres, Croatia (Hrvatska); Glaxo Group, Austria; Glaxo Group, Lithuania; GlaxoSmithKline, Argentina; GlaxoSmithKline, Australia; GlaxoSmithKline, Canada; GlaxoSmithKline, China; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Ecuador; GlaxoSmithKline, Egypt; GlaxoSmithKline, Spain; GlaxoSmithKline, Finland; GlaxoSmithKline, Georgia; GlaxoSmithKline, Greece; GlaxoSmithKline, Hungary; GlaxoSmithKline, Indonesia; GlaxoSmithKline, Israel; GlaxoSmithKline, Italy; GlaxoSmithKline, Japan; GlaxoSmithKline, Norway; GlaxoSmithKline, Philippines; GlaxoSmithKline, Romania; GlaxoSmithKline, Sweden; GlaxoSmithKline, Slovakia; GlaxoSmithKline, Thailand; GlaxoSmithKline, United States; GlaxoSmithKline, Vietnam; GlaxoSmithKline, South Africa; GSK, Turkey; Navamedic AB, Sweden; Sanofi-Aventis, Lebanon; Sanofi-Aventis, Oman; Glaxo Group, Poland; GlaxoSmithKline, Serbia


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.